2076975 2077203
최종편집 2024-04-15 22:42 (월)
HER2-positive locally advanced or metastatic breast cancer treatment 'Tukysa' lands in Korea
상태바
HER2-positive locally advanced or metastatic breast cancer treatment 'Tukysa' lands in Korea
  • Hyeokgi Lee, Newsmp
  • 승인 2023.12.15 20:30
  • 댓글 0
이 기사를 공유합니다

[Newsmp] The Ministry of Food and Drug Safety of South Korea (MFDS, Minister Oh Yoo-kyung) said Thursday that it had approved two doses (50mg, 150mg) of the new breast cancer drug ‘Tukysa (ingredient: tucatinib)’ developed by MSD Korea.

Tukysa is given in combination with capecitabine and trastuzumab and is used after at least 2 other treatments for HER2-positive cancer have already been treated.

Tucatinib is a tyrosine kinase inhibitor (TKI) that selectively and potently inhibits the HER2 receptor that is overexpressed in cancer cells. It blocks the HER2 pathway signaling, which inhibits tumor cell survival, proliferation, and metastasis, and induces tumor cell death.

"We expect Tukysa to provide a new treatment opportunity for HER2-positive patients who have not responded well to other treatments," MFDS said. "We will continue to work hard to ensure that patients have access to the latest and most effective treatments as quickly as possible, based on our expertise in regulatory science."


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.